The role of gut microbial β-glucuronidase in drug disposition and development

Drug Discov Today. 2022 Oct;27(10):103316. doi: 10.1016/j.drudis.2022.07.001. Epub 2022 Jul 9.

Abstract

Gut microbial β-glucuronidase (gmGUS) is involved in the disposition of many endogenous and exogenous compounds. Preclinical studies have shown that inhibiting gmGUS activity affects drug disposition, resulting in reduced toxicity in the gastrointestinal tract (GIT) and enhanced systemic efficacy. Additionally, manipulating gmGUS activity is expected to be effective in preventing/treating local or systemic diseases. Although results from animal studies are promising, challenges remain in developing drugs by targeting gmGUS. Here, we review the role of gmGUS in host health under physiological and pathological conditions, the impact of gmGUS on the disposition of phenolic compounds, models used to study gmGUS activity, and the perspectives and challenges in developing drugs by targeting gmGUS.

Keywords: Drug development; Drug disposition; Druggable target; Gut microbial β-glucuronidase.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Gastrointestinal Microbiome*
  • Gastrointestinal Tract
  • Glucuronidase* / pharmacology

Substances

  • Glucuronidase